Moderna’s mRNA flu vaccine gets thumbs up from federal vaccine panel
Moderna’s investigational mRNA flu vaccine mRNA-1010 (mFlusiva) for adults 50–64 received unanimous support from the FDA’s VRBPAC, recommending approval and accelerated approval for ages 65+. The panel backed the decision based on a phase 3 trial of nearly 41,000 adults; relative vaccine efficacy was 27% vs standard-dose shots. Moderna must run a phase 4 post-marketing study for the 65+ group.
Regulatory endorsement increases odds of FDA approval and can re-rate near-term commercialization expectations for mRNA-1010.
VRBPAC unanimously recommended FDA approval of Moderna’s mRNA-1010 flu vaccine (mFlusiva) for ages 50–64 and accelerated approval for 65+.
Moderately positive bias into the FDA decision window (by Aug 5), with volatility tied to any remaining FDA questions or post-marketing study requirements.
Background
FDA previously questioned the phase 3 comparator design (standard-dose vs preferred high-dose), then reversed after Moderna proposed a revised regulatory approach.
Why it matters
A unanimous VRBPAC vote recommends approval for 50–64 and accelerated approval for 65+, requiring a phase 4 post-marketing effectiveness study for the older group; this sets up a clear catalyst into the FDA’s Aug 5 decision.
Market relevance
This is a concrete regulatory milestone with defined indications and an FDA decision deadline, creating a tradable event window for MRNA.
Market effects
Strengthens the mRNA vaccine platform narrative for seasonal indications and may improve sentiment toward other late-stage mRNA vaccine programs.
Primarily US regulatory-driven; could spill into broader North American biotech risk appetite around FDA timelines.
VRBPAC review draws on multi-country phase 3 data, supporting global commercialization credibility if FDA follows through.
Alternative perspectives
VRBPAC recommendation is not final FDA approval; prior comparator/regulatory uncertainty suggests the FDA could still request additional evidence or impose conditions.
The article flags reactogenicity (more fever) and limited coverage of immunocompromised/frail older adults—potential FDA labeling or post-marketing requirements could temper upside.
Key entities
- companyModerna
mRNA-1010 developer; received VRBPAC recommendation for mFlusiva approval and accelerated approval.
- regulator_panelFDA VRBPAC
Advisory committee that voted unanimously to recommend approval and accelerated approval.
- productmFlusiva (mRNA-1010)
Investigational mRNA influenza vaccine for adults 50–64; accelerated approval sought for 65+.
